Compare Natera Inc. Common Stock (NTRA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Raymond James Financial, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Raymond James Financial, Inc. for 75 Days on average.
| NTRA | RJF | |
|---|---|---|
Market Cap | $57.03B | $30.15B |
Volume | 1,131,157 | 980,106 |
Sector | Health | Financials |
52-Week High | $425.64 | $181.18 |
52-Week Low | $179.42 | $140.89 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $56.18B | $24.02B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Raymond James Financial (RJF) trades at $156.78, down 1.18% with bearish technical indicators but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.14 exceeding expectations. Revenue growth has been steady from $10.9B in 2022 to $13.8B in 2025, with net income margins above 15%. Recent leadership transitions and PGA TOUR sponsorship highlight strategic developments.
The outlook remains positive with a $178.50 consensus price target representing 14% upside potential. Analyst consensus leans Hold (55.56%) with no Sell ratings, indicating cautious optimism. Key risks include volatile cash flows from investing activities and brokerage market sensitivity. The company's strong profitability metrics and institutional accumulation support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
